After dose of Hep B, HBIG can be added to the record.  For more information MCIR System Release PDF. 

DTaP and Tdap updates, removal of PCV13 from status forecasting for routine assessments for all.  For more information MCIR System Release PDF

HepB doses not evaluating, HPV not showing in status screen.  For more information MCIR System Release PDF

Forecast and evaluate CVX 316 MenABCWY (Penbraya)  For more information MCIR System Release PDF

We have been notified that the Michigan Care Improvement Registry (MCIR) is not accurately forecasting, displaying, or assessing Hepatitis B and HPV9 vaccine histories. These issues are currently being worked on with the highest priority. We apologize for any inconvenience this may cause in your efforts to keep your patients up to date.

Please refer to the Child and Adolescent Immunization Schedule by Age and the Adult Immunization Schedule by Age for any questions or concerns you may have when reviewing your patient’s immunization records for vaccine recommendations and intervals.

• Dose 3 PCV should forecast for at least 12 months of age and at least 8 weeks as final dose if previous dose is 7-11 months of age
• Td/Tdap booster should be 10 years for accelerated date.
• Update RSV MAB forecasting and evaluation, review RSV vaccine for 24-25 season will become effective on 4/1/2024
• CVX 30 HepB IG manufacturer’s list has been updated to add Grifols Therapeutics
• The issue with HL7 Rejection resulting in deduction from Beyfortus inventory has been resolved.

For more information, see MCIR Release Notes PDF

Investigate COVID-19 forecasting results for mixed series administration.  For more information see MCIR Release Notes PDF

RSV MAB recommendation for “consider” has been removed.  For more information see MCIR Release Notes PDF

Update to “Consider” recommendation for some RSV recipients. More Information see MCIR Release PDF  

Novavax COVID-19 vaccine added.  For more information see MCIR Release Notes PDF